A 52-year-old man with a 10-year history of type 2 diabetes mellitus presents to the pain clinic with a 6-month history of burning pain in both feet, worse at night, associated with numbness and tingling. Physical examination reveals diminished vibration sense and absent ankle reflexes bilaterally. Monofilament testing shows sensory loss over the dorsum of both feet. He has tried paracetamol 1 g four times daily and ibuprofen 400 mg three times daily without relief. His HbA1c is 8.2%. What is the most appropriate next step in pharmacological management?

Explanation

## Diagnosis: Diabetic Peripheral Neuropathic Pain This patient has classic diabetic peripheral neuropathy (DPN) with sensory loss, diminished reflexes, and burning neuropathic pain unresponsive to NSAIDs and paracetamol. ## First-Line Pharmacotherapy for Neuropathic Pain **Key Point:** Pregabalin and gabapentin are first-line agents for neuropathic pain, including diabetic neuropathy, as recommended by major guidelines (ADA, IASP, EFNS). **High-Yield:** Pregabalin mechanism: - Binds to α~2~δ subunit of voltage-gated calcium channels - Reduces release of excitatory neurotransmitters (glutamate, noradrenaline) - Effective in both neuropathic and nociceptive pain - Typical dose: 150–600 mg/day in divided doses - Onset: 2–4 weeks; requires gradual titration ## Why Pregabalin Is Superior Here | Feature | Pregabalin | Morphine | Capsaicin | Tramadol | |---------|-----------|----------|-----------|----------| | **First-line for DPN** | ✓ Yes | ✗ No | Adjunct only | Second-line | | **Evidence base** | Strong RCT data | Limited in neuropathy | Local effect only | Weaker evidence | | **Systemic side effects** | Dizziness, weight gain | Respiratory depression, addiction | Minimal | Seizure risk, serotonin syndrome | | **Renal clearance** | Requires dose adjustment | Hepatic metabolism | None | Hepatic metabolism | **Clinical Pearl:** Neuropathic pain responds poorly to opioids and NSAIDs alone; gabapentinoids (pregabalin, gabapentin) and SNRIs (duloxetine, venlafaxine) are the cornerstones of treatment. ## Treatment Algorithm for Diabetic Neuropathic Pain ```mermaid flowchart TD A["Diabetic neuropathic pain"]:::outcome --> B["Optimize glycemic control"]:::action B --> C{"Pain severity?"}:::decision C -->|Mild-moderate| D["First-line: Pregabalin or Gabapentin"]:::action C -->|Moderate-severe| E["Consider combination: Pregabalin + SNRI"]:::action D --> F{"Adequate response at 4 weeks?"}:::decision F -->|Yes| G["Continue; monitor for tolerance"]:::action F -->|No| H["Increase dose or add SNRI"]:::action E --> I["Assess at 4–6 weeks"]:::action I --> J{"Inadequate response?"}:::decision J -->|Yes| K["Consider topical agents or tramadol"]:::action J -->|No| L["Maintain current regimen"]:::action ``` **Key Point:** Morphine is reserved for severe neuropathic pain refractory to first-line agents and carries risks of dependence, tolerance, and hyperalgesia in chronic use. **Tip:** Always optimize glycemic control (target HbA1c <7%) as the foundation; this patient's HbA1c of 8.2% indicates suboptimal control and should be addressed in parallel.